Gain Therapeutics (GANX) Research & Development (2020 - 2026)
Gain Therapeutics (GANX) posted quarterly Research & Development of $2.8 million for Q1 2026, up 22.43% year-over-year from $2.3 million in Q1 2025, and up 17.72% quarter-over-quarter from $2.3 million in Q4 2025.
Gain Therapeutics (GANX) Research & Development (2020 - 2026) Analysis & Trends
Gain Therapeutics' Research & Development history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Research & Development rose 22.43% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $10.7 million (up 1.69% YoY), while the FY2025 annual figure was $10.2 million, down 5.36% from the prior year.
- Research & Development for Q1 2026 stood at $2.8 million, up from $2.3 million in the prior quarter.
- The five-year high for Research & Development was $4.4 million in Q2 2024, with the low at $1.2 million in Q4 2024.
- The 5-year median for Research & Development is $2.5 million (2024), against an average of $2.6 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development sank 48.41% in 2024, then soared 91.65% in 2025.
- Gain Therapeutics' Research & Development stood at $2.3 million in 2022, then climbed by 4.4% to $2.4 million in 2023, then tumbled by 48.41% to $1.2 million in 2024, then soared by 91.65% to $2.3 million in 2025, then grew by 17.72% to $2.8 million in 2026.
- Business Quant data shows GANX's Research & Development at $2.8 million in Q1 2026, $2.3 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Gain Therapeutics | 85.12 Mn | 85.12 Mn | - | 2.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.14 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.35 Mn |
| Sep 30, 2025 | 2.85 Mn |
| Jun 30, 2025 | 2.76 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 1.22 Mn |
| Sep 30, 2024 | 2.62 Mn |
| Jun 30, 2024 | 4.44 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 2.37 Mn |
| Sep 30, 2023 | 2.37 Mn |
| Jun 30, 2023 | 3.99 Mn |
| Mar 31, 2023 | 2.79 Mn |
| Dec 31, 2022 | 2.27 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 2.58 Mn |
| Mar 31, 2022 | 1.56 Mn |
| Dec 31, 2021 | 1.47 Mn |
| Sep 30, 2021 | 2.48 Mn |